SLNO
Soleno Therapeutics Inc.
Latest News for SLNO
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Soleno Therapeutics (SLNO) and Viridian Therapeutics (VRDN). Sole......
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Soleno Therapeutics (SLNO) and Viridian Therapeutics (VRDN). Sole......
Shares in Soleno Therapeutics ($SLNO) zoomed 28% higher in pre-market trading on reports that it could be bought for $2.5 billion by peer Neurocrin......
In March 2025, the company celebrated FDA approval and touted VYKAT XR as safe, effective, and positioned for a strong commercial launch. Inv......
Important Notice Regarding Alleged DCCR Safety Data Misrepresentations NEW YORK, March 26, 2026 — Levi & Korsinsky, LLP notifies investors in Solen......
Soleno (SLNO) promoted VYKAT XR as the first approved treatment for hyperphagia associated with Prader-Willi syndrome, a rare genetic disorder. Com......
Soleno (SLNO) promoted VYKAT XR as the first approved treatment for hyperphagia associated with Prader-Willi syndrome, a rare genetic disorder. Com......
In a report released today, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Soleno Therapeutics, with a price target of $123.00. A......
News data is sourced from MarketXLS API and updated regularly.
Showing 8 of 8 articles.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SLNO | $52.35 | 0% | 17.62M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Soleno Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW